Serum levels of eosinophil cationic protein reflect the state of in vitro degranulation of blood hypodense eosinophils in atopic dermatitis

Journal of Dermatology

Volumn 23, Issue 6, 1996, Pages 382-388

  Miyasato, Minoru ^a   Tsuda, Shingo ^a   Nakama, Takekuni ^a   Kato, Keiko ^a   Kitamura, Naohisa ^a   Nagaji, Junko ^a   Sasai, Yoichiro ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

atopic dermatitis; ECP; EG2; hypodense eosinophil

Indexed keywords

EOSINOPHIL CATIONIC PROTEIN;

ADULT; ARTICLE; ATOPIC DERMATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DEGRANULATION; DISEASE SEVERITY; EOSINOPHIL; FEMALE; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; LEUKOCYTE COUNT; MALE; PROTEIN DETERMINATION; TRANSMISSION ELECTRON MICROSCOPY;

EID: 0030038754     PISSN: 03852407     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1346-8138.1996.tb04038.x     Document Type: Article

References (30)

1. Leiferman KM: Eosinophils in atopic dermatitis, Allergy, 44: 20-26, 1989.
2. Leiferman KM, Ackerman SJ, Sampson HA, Haugen HS, Venencie PY, Gleich GJ: Dermal deposition of eosinophil-granule major basic protein in atopic dermatitis. Comparison with onchocerciasis, N Engl J Med, 313: 282-285, 1985.
3. Juhlin L, Venge P: Eosinophil cationic protein (ECP) in skin disorders, Acta Derma Venereal, 71: 495-501, 1991.
4. Maeda K, Yamamoto K, Tanaka Y, Anan S, Yoshida H: The relationship between eosinophils, OKT6-positive cells and house dust mite (HDM) antigens in naturally occurring lesions of atopic dermatitis, J Dermatol Sci, 3: 151-156, 1992.
5. Bruyzeel-Koomen CAFM, Van Wichen DF, Spry CJF, Venge P, Bruyzeel PBL: Active participation of eosinophils in patch test reactions to inhalant allergens in patients with atopic dermatitis, Br J Dermatol, 118: 229-238, 1988.
6. Winqvist I, Olofsson T, Olsson I: Mechanism for eosinophil degranulation: Release of eosinophil cationic protein, Immunology, 51: 1-8, 1984.
7. Czech W, Krutmann J, Schopf E, Kapp A: Serum eosinophil cationic protein (ECP) is a sensitive measure for disease activity in atopic dermatitis, Br J Dermatol, 126: 351-355, 1992.
8. Jakob T, Hermann K, Ring J: Eosinophil cationic protein in atopic eczema, Arch Dermatol Res, 283: 5-6, 1991.
9. Kapp A, Czech W, Krustmann J, Schopf E: Eosinophil cationic protein in sera of patients with atopic dermatitis, J Am Acad Dermatol, 24: 555-558, 1991.
10. Furue M, Sugiyama H, Tsukamoto K, Ohta N, Tamaki K: Serum soluble IL-2 receptor (sIL-2R) and eosinophil cationic protein (ECP) levels in atopic dermatitis, J Dermatol Sci, 7: 89-95, 1994.
11. Tsuda S, Kato K, Miyasato M, Sasai Y: Eosinophil involvement in atopic dermatitis as reflected by elevated serum levels of eosinophil cationic protein, J Dermatol (Tokyo), 19: 208-213, 1992.
12. Miyasato M, Taguchi K, Kitamura N, Kato K, Tsuda S: Eosinophil chemiluminescence response to cytokines and opsonized zymosans in atopic dermatitis, Int Arch Allergy Immunol, 104 (suppl): 24-26, 1994.
13. Miyasato M, Tsuda S, Kitamura N, Shirouzu K, Nakama T, Sasai Y: Purification of human blood eosinophils by a combination method using anti-CDI6 monoclonal antibody, immunobeads, and Nycodenz density gradient, J Dermatol Sci, 10: 118-129, 1995.
14. Tai PC, Spry CJF, Peterson C, Venge P, Olsson I: Monoclonal antibodies distinguish between storage and secreted forms of eosinophil cationic peptide, Nature, 309: 182-184, 1984.
15. Hanifin JM, Rajka G: Diagnostic futures of atopic dermatitis, Acta Derma Venereol, 92: 44-47, 1981.
16. Rajka G, Langeland T: Grading of the severity of atopic dermatitis, Acta Derma Venereol, 144: 13-14, 1989.
17. Miyasato M, Iryo K, Kasada M, Tsuda S: Varied density of eosinophils in patients with atopic dermatitis reflecting treatment with antiallergic drug, J Invest Dermatol, 90: 589, 1988. (abstract)
18. Henderson WR, Chi Y: Ultrastructural characterization and morphometric analysis of human eosinophil degranulation, J Cell Sci, 73: 33-45, 1985.
19. Caufield JP, Hein A, Rothenberg ME, et al: A morphologic study of normodense and hypodense human eosinophils that are derived in vitro and in vivo, AmJ Pathol, 137: 27-41, 1990.
20. Soter NA: Morphology of atopic eczema, Allergy, 9: 16-19, 1989.
21. Lever R, Turbitt M, Sanderson A, MacKie R: Immunophonotyping of the cutaneous infiltrating and of the mononuclear cells in the peripheral blood in patients with atopic dermatitis, J Invest Dermatol, 89: 4-7, 1987.
22. Van der Heiden FL, Wierenga EA, Bos JD, Kapsenberg ML: High frequency of IL-4 producing CD4+ allergen-specific T lymphocytes in atopic dermatitis lesional skin, J Invest Dermatol, 97: 389-394, 1991.
23. Mosmann TR, Cherwinski H, Bond MW, Gieldlin MA, Coffman RL: Two types of murine helper T cell clone. I. Diffinition according to profiles of lymphokine activities and secreted proteins, J Immunol, 136: 2348-2357, 1986.
24. Sonoda Y, Arai N, Ogawa M: Humoral regulation of eosinophilopoiesis in vitro: Analysis of the targets of interleukin-3, granulocyte/macrophage colony-stimulating factor (GM-CSF), and interleukin-5, Leukemia, 3: 14-18, 1989.
25. Owen WF, Rothenberg MF, Silberstein DS, et al: Regulation of human eosinophil viability, density, and function by granulocyte/macrophage colony-stimulating factor in the presence of 3T3 fibroblasts, J Exp Med, 166: 129-141, 1987.
26. Rothenberg ME, Owen WF, Silberstein DS, et al: Human eosinophils have prolonged survival, enhanced functional properties, and become hypodense when exposed to human interleukin 3, J Clin Invest, 81: 1986-1992, 1988.
27. Rothenberg ME, Petersen JE, Stevens RL, et al: IL-5-dependent conversion of normodense eosinophils to the hypodense phenotype uses 3T3 fibroblasts for enhanced viability, accelerated hypodensity, and sustained antibody-dependent cytotoxicity, J Immunol, 143: 2311-2316, 1989.
28. Taylor RS, Baadsgaad O, Hamrnerberg C, Cooper KD: Hyperstimulatory CD1a+ CD1b+ CD36+ Langerhans cells are responsible for increased autologous T lymphocyte reactivity to lesional epidermal cells of patients with atopic dermatitis, J Immunol, 147: 3794-3802, 1991.
29. Wang JM, Rambaldi A, Biondi A, Chen G, Sanderson CJ, Maantovani A: Recombinant human interleukin 5 is a selective eosinophil chemoattractant, Eur J Immunol, 19: 701-705, 1989.
30. Fujisawa T, Abu GR, Kita H, Sanderson CJ, Gleich GJ: Regulatory effect of cytokines on eosinophil degranulation, J Immunol, 144: 642-646, 1990.